Chronic venous insufficiency: Molecular abnormalities and ulcer formation

The Vein Book

Volumn , Issue , 2007, Pages 79-87

  Raffetto, Joseph D ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46749109028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369515-4/50011-9     Document Type: Chapter

References (54)

1. Flanigan DP, Goodreau JJ, Burnham SJ, Bergan JJ, Yao JST Vascular laboratory diagnosis of clinically suspected acute deep vein thrombo-sis. Lancet. 1978, 2:331-334.
2. Bergan JJ Surgical management of primary and recurrent varicose veins. Handbook of venous disorders: Guidelines of the American venous forum 1996, 394-415. Chapman and Hall, New York. 1e. P. Gloviczki, J.S.T. Yao (Eds.).
3. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: The cause of lipodermatosclerosis and venous ulceration. J. Br Med. 1988, 285:1071-1072.
4. Gandhi RH, Irizarry E, Neckman GB, Halpern VJ, Mulcare RJ, Tilson MD. Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc.Surg. 1994, 20:814-820.
5. Parra JR, Cambria RA, Hower CD, Hower CD, Dassow MS, Freischlag JA, et al. Tissue inhibitor of metalloproteinase-1 is increased in the saphenophemoral junction of patients with varices in the leg. J Vasc. Surg. 1998, 28:669-675.
6. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP Increased TIMP/MMP ratio in varicose veins: A possible explanation for extracellular matrix accumulation J. Pathol. 2000, 192:105-112.
7. Jacob MP, Cazaubon M, Scemama A, Prie D, Blanchet F, Guillin MC, Michel JB. Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 2002, 106:535-538.
8. Gillespie DL, Patel A, Fileta B, Chang A, Barnes S, Flagg A, et al. Varicose veins possess greater quantities of MMP-1 than normal veins demonstrate regional variation in MMP-1 and MMP-13. J Surg. Res. 2002, 106:233-238.
9. Kowalewski R, Sobolewski K, Wolanska M, Gacko M. Matrix metal-loproteinases in the vein wall Int. Angiol. 2004, 23:164-169.
10. Sansilvestri-Morel P, Nonotte I, Fournet-Bourguignon MP, Rupin A, Fabiani JN, Verbeuren TJ, Vanhoutte PM. J Vasc. Res. 1998, 35:115-123.
11. Sansilvestri-Morel P, Rupin A, Jaisson S, Fabiani JN, Verbeuren TJ, Vanhoutte PM. Synthesis of collagen is dysregulated in cultured fibro-blasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation. 2002, 106:479-483.
12. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998, 281:1309-1312.
13. Ascher E, Jacob T, Hingorani A, Gunduz Y, Mazzariol F, Kallakuri S. Programmed cell death (apoptosis) its role in the pathogenesis of lower extremity varicose veins. Ann Vasc. Surg. 2000, 14:24-30.
14. Ducasse E, Giannakakis K, Chevalier J, Dasnoy D, Puppinck P, Spe-ziale F, et al. Eur. J. Vasc Endovasc. Surg. 2005, 29:316-323.
15. Takase S, Pascarella L, Bergan JJ, Schmid-Schonbein GW. Hyperten-sion-induced venous valve remodeling. J Vasc. Surg. 2004, 39:1329-1334.
16. Pascarella L, Schmid-Schonbein GW, Bergan JJ. An animal model of venous hypertension: The role of inflammation in venous valve failure. J Vasc. Surg. 2005, 41:303-311.
17. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: The cause of lipodermatosclerosis and venous ulceration. Br Med. J. 1982, 285:1071-1072.
18. Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: A possible mech-anism for trophic changes in the skin. Br Med. J. 1988, 296:1693-1695.
19. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: A new hypothesis. Br Med. J. 1988, 296:1726-1727.
20. Falanga V, Eaglstein WH. The "trap" hypothesis of venous ulceration. Lancet. 1993, 341:1006-1008.
21. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J. Surg. 1991, 78:210-211.
22. Wilkinson LS, Bunker C, Edwards JC, Scurr JH, Coleridge Smith PD. Leukocytes: Their role in the etiopathogensis of skin damage in venous disease. J Vasc. Surg. 1993, 17:669-675.
23. Pappas PJ, Fallek SR, Garcia A, Araki CT, Back TL, Duran WN, Hobson RW Role of leukocyte activation in patients with venous stasis ulcers. J Surg. Res. 1995, 59:553-559.
24. Pappas PJ, Teehan EP, Fallek SR, Garcia A, Araki CT, Back TL, et al. Diminished mononuclear cell function is associated with chronic venous insufficiency. J Vasc. Surg. 1995, 22:580-586.
25. Pappas PJ, DeFouw DO, Venezio LM, Gorti R, Padberg FT Jr, Silva MB, et al. Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. J Vasc. Surg. 1997, 26:784-795.
26. Weyl A, Vanscheidt W, Weiss JM, Pesschen M, Schopf E, Simon J. Expression of the adhesion molecules ICAM-1 VCAM-1 E-selectins and their ligands VLA-4 and LFA-1 in chronic venous leg ulcers J. Am Acad. Dermatol. 1996, 34:418-423.
27. Saharay M, Shields DA, Porter JB, Scurr JH, Coleridge Smith PD Leukocyte activity in the microcirculation of the led in patients with chronic venous disease. J Vasc. Surg. 1997, 26:265-273.
28. Takase S, Schmid-Schonbein G, Bergan JJ. Leukocyte activation in patients with venous insufficiency. J Vasc. Surg. 1999, 30:148-156.
29. Stanley AC, Park HY, Phillips TJ, Russakovsky V, Menzoian JO Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc. Surg. 1997, 26:994-1001.
30. Agren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E. Proliferation and mitogenic response to PDGF-BB of fibroblasts iso-lated from chronic venous leg ulcers is ulcer-age dependent. J Invest. Dermatol. 1999, 112:463-469.
31. Mendez MV, Stanley AC, Park HY, Shon K, Phillips TJ, Menzoian JO. Fibroblasts cultured from venous ulcers display cellular character-istics of senescence. J Vasc. Surg. 1998, 28:876-883.
32. Raffetto JD, Mendez MV, Phillips TJ, Park HY, Menzoian JO. The effect of passage number on fibroblast cellular senescence in patients with chronic venous insufficiency with without ulcer. Am J. Surg. 1999, 178:107-112.
33. Seidman CS, Raffetto JD, Marien BJ, Kroon CS, Seah CC, Menzoian JO. bFGF induced alterations in cellular markers of senescence in growth rescued fibroblasts from chronic venous ulcer venous reflux patients. Ann Vasc. Surg. 2003, 17:239-244.
34. Raffetto JD, Mendez VM, Marien BJ, Byers HR, Phillips TJ, Park HY, Menzoian JO. Changes in cellular motility cytoskeletal actin in fibroblasts from patients with chronic venous disease and in newborn fibroblasts in the presence of chronic. J Vasc. Surg. 2001, 33:1233-1241.
35. Vasquez R, Marien BJ, Gram C, Goodwin DG, Menzoian JO, Raffetto JD. Proliferative capacity of venous ulcer fibroblasts in the presence of platelet-derived growth factor. Vasc Endovascular. Surg. 2004, 38:355-360.
36. Raffetto JD, Vasquez R, Goodwin DG, Menzoian JO. Mitogen acti-vated protein kinase pathway regulates cell proliferation in venous ulcer fibroblasts. Vasc Endovasc. Surg. 2006, 40:59-66.
37. Galkowska H, Olszewsk WL, Wojewodzka U, Mijal J, Filipiuk E. Expression of apoptosis-and cell cycle-related proteins in epidermis of venous leg and diabetic foot ulcers. Surgery. 2003, 134:213-220.
38. Galkowska H, Olszewsk WL, Wojewodzka U. Keratinocyte and dermal vascular endothelial cell capacities remain unimpaired in the margin of chronic venous ulcer. Arch Dermatol. Res. 2005, 296:286-295.
39. Ongenae KC, Phillips TJ, Park HY. Level of fibronectin mRNA is markedly increased in human chronic wounds. Dermatol. Surg. 2000, 26:447-451.
40. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules possible trapping of transforming growth factor-beta in venous ulceration. Br J. Dermatol. 1995, 132:79-85.
41. Hasan A, Murata H, Falabella A, Ochoa S, Zhou L, Badiavas E, Falanga V. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol. Sci. 1997, 16:59-66.
42. Pappas PJ, You R, Rameshwar P, Gorti R, DeFouw DO, Phillips CK, et al. Dermal tissue fibrosis in patients with chronic venous insuffi-ciency is associated with increased transforming growth factor-beta1 gene expression and protei. J Vasc. Surg. 1999, 30:1129-1145.
43. Lal BK, Saito S, Pappas PJ, Padberg FT, Cerveira JJ, Hobson RW, Duran WN. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. J Vasc. Surg. 2003, 37:1285-1293.
44. Kim BC, Kim HT, Park SH, Cha JS, Yufit T, Kim SJ, Falanga V. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta type II receptor expression. J. Cell Physiol. 2003, 195:331-336.
45. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest. Dermatol. 1993, 101:64-68.
46. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen TY. Matrix metalloproteinases gelatinase, and collagenase, in chronic leg ulcers. J Invest. Dermatol. 1996, 106:1119-1124.
47. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluid from human pressure ulcers contain elevated matrix metalloproteinase levels and activity to surgical wound fluids. J Invest. Dermatol. 1996, 107:743-748.
48. Hoffman R, Starkey S, Coad J. Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. J Invest. Dermatol. 1998, 111:1140-1144.
49. Cook H, Stephens P, Davies KJ, Harding KG Thomas DW. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2 and MMP-2 activity. J Invest. Dermatol. 2000, 115:225-233.
50. Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: Implications for venous ulcer formation. J Invest. Dermatol. 1998, 111:822-827.
51. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT, et al. Role of matrix metalloproteinases 1, 2 and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc. Surg. 2001, 34:930-938.
52. Hieta N, Impola U, Lopez-Otin C, Saarialho-Kere U, Kahari VM. Matrix metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture. J Vasc. Surg. 2003, 121:997-1004.
53. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Rep. Reg. 1993, 1:181-186.
54. Seah CC, Phillips TJ, Howard CE, Panova IP, Hayes CM, Asandra AS, Park HY. Chronic wound fluid suppresses proliferation of dermal fibro-blasts through a Ras-mediated signaling pathway. J Invest. Dermatol. 2005, 124:466-474.